Takeda Pharmaceutical Company Limited (TAK): Price and Financial Metrics


Takeda Pharmaceutical Company Limited (TAK): $14.42

-0.13 (-0.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TAK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 465

in industry

TAK POWR Grades


  • Value is the dimension where TAK ranks best; there it ranks ahead of 99.34% of US stocks.
  • TAK's strongest trending metric is Growth; it's been moving down over the last 160 days.
  • TAK ranks lowest in Momentum; there it ranks in the 11th percentile.

TAK Stock Summary

  • TAK has a market capitalization of $50,066,264,442 -- more than approximately 94.62% of US stocks.
  • Price to trailing twelve month operating cash flow for TAK is currently 0.04, higher than just 0.9% of US stocks with positive operating cash flow.
  • Takeda Pharmaceutical Co Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 2,428.84%, greater than the shareholder yield of 99.64% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Takeda Pharmaceutical Co Ltd are SMFG, CAJ, HMC, IRCP, and NMR.
  • Visit TAK's SEC page to see the company's official filings. To visit the company's web site, go to www.takeda.com.

TAK Stock Price Chart Interactive Chart >

Price chart for TAK

TAK Price/Volume Stats

Current price $14.42 52-week high $19.97
Prev. close $14.55 52-week low $13.17
Day low $14.38 Volume 755,476
Day high $14.55 Avg. volume 3,192,210
50-day MA $13.88 Dividend yield 4.54%
200-day MA $15.80 Market Cap 45.63B

Takeda Pharmaceutical Company Limited (TAK) Company Bio


Takeda Pharmaceutical Company Limited is engaged in research and development, manufacturing, sales and marketing, and import and export of pharmaceutical drugs. The Company focuses on the core therapeutic areas of oncology, gastrointestinal, and central nervous system disease.


TAK Latest News Stream


Event/Time News Detail
Loading, please wait...

TAK Latest Social Stream


Loading social stream, please wait...

View Full TAK Social Stream

Latest TAK News From Around the Web

Below are the latest news stories about Takeda Pharmaceutical Co Ltd that investors may wish to consider to help them evaluate TAK as an investment opportunity.

Ridgewood Investments LLC Buys Vale SA, Activision Blizzard Inc, Calavo Growers Inc, Sells ...

Investment company Ridgewood Investments LLC (Current Portfolio) buys Vale SA, Activision Blizzard Inc, Calavo Growers Inc, FedEx Corp, Takeda Pharmaceutical Co, sells General Dynamics Corp, Merck Inc, Comcast Corp, U.S.

Yahoo | January 18, 2022

Top Pharmaceutical Stocks for Q1 2022

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2022.

Yahoo | January 13, 2022

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference

OSAKA, Japan & CAMBRIDGE, Mass., January 10, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through FY2030. Presenting at the 40th Annual J.P. Morgan Healthcare Conference, Christophe Weber, Takeda’s President and Chief Executive Officer, reinforced the mid-term revenue growth potential of its 14 global

Yahoo | January 10, 2022

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors

OSAKA, Japan & LONDON, January 10, 2022--Takeda exercised its option to acquire Adaptate Biotherapeutics, adding a gamma delta T-cell engager platform to Takeda's immuno-oncology portfolio.

Yahoo | January 10, 2022

FDA Rejects Takeda''s Eosinophilic Esophagitis Candidate, Asks For Additional Study

Takeda Pharmaceutical Co Ltd (NYSE: TAK ) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral suspension) for eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. The CRL indicates the FDA has completed its review of the TAK-721 NDA and determined that it cannot be approved in Full story available on Benzinga.com

Benzinga | December 22, 2021

Read More 'TAK' Stories Here

TAK Price Returns

1-mo 3.74%
3-mo 2.85%
6-mo -12.73%
1-year -15.63%
3-year -22.87%
5-year -25.20%
YTD 5.80%
2021 -23.58%
2020 -5.97%
2019 19.31%
2018 -40.08%
2017 36.91%

TAK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TAK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.2011 seconds.